These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20063996)

  • 1. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
    Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
    Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
    Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
    Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
    Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B; Keita M; Megnassan E; Frecer V; Miertus S
    Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
    Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
    Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
    Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
    Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
    Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
    Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
    Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
    J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 13. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
    J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
    Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
    Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.
    Saify ZS; Azim MK; Ahmad W; Nisa M; Goldberg DE; Hussain SA; Akhtar S; Akram A; Arayne A; Oksman A; Khan IA
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1282-6. PubMed ID: 22204908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
    Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
    Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids.
    Degliesposti G; Kasam V; Da Costa A; Kang HK; Kim N; Kim DW; Breton V; Kim D; Rastelli G
    ChemMedChem; 2009 Jul; 4(7):1164-73. PubMed ID: 19437467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
    Nöteberg D; Schaal W; Hamelink E; Vrang L; Larhed M
    J Comb Chem; 2003; 5(4):456-64. PubMed ID: 12857114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
    Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
    Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
    Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.